Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

MLA

Meca-Lallana, J. E., et al. “Consensus Statement on the Use of Alemtuzumab in Daily Clinical Practice in Spain.” Neurologia, vol. 37, no. 8, Oct. 2022, pp. 615–30. EBSCOhost, https://doi.org/10.1016/j.nrleng.2019.11.001.

APA

Meca-Lallana, J. E., Fernández-Prada, M., García Vázquez, E., Moreno Guillén, S., Otero Romero, S., Rus Hidalgo, M., Villar Guimerans, L. M., Eichau Madueño, S., Fernández Fernández, Ó., Izquierdo Ayuso, G., Álvarez Cermeño, J. C., Arnal García, C., Arroyo González, R., Brieva Ruiz, L., Calles Hernández, C., García Merino, A., González Plata, M., Hernández Pérez, M. Á., Moral Torres, E., … Montalbán Gairin, X. (2022). Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia, 37(8), 615–630. https://doi.org/10.1016/j.nrleng.2019.11.001

Chicago

Meca-Lallana, J E, M Fernández-Prada, E García Vázquez, S Moreno Guillén, S Otero Romero, M Rus Hidalgo, L M Villar Guimerans, et al. 2022. “Consensus Statement on the Use of Alemtuzumab in Daily Clinical Practice in Spain.” Neurologia 37 (8): 615–30. doi:10.1016/j.nrleng.2019.11.001.